- Home
- BEAM vs SKE Comparison
BEAM vs SKE Comparison
Compare BEAM & SKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- SKE
- Stock Information
- Founded
- BEAM 2017
- SKE 1979
- Country
- BEAM United States
- SKE Canada
- Employees
- BEAM N/A
- SKE N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- SKE Precious Metals
- Sector
- BEAM Health Care
- SKE Basic Materials
- Exchange
- BEAM Nasdaq
- SKE Nasdaq
- Market Cap
- BEAM 1.6B
- SKE 1.4B
- IPO Year
- BEAM 2020
- SKE N/A
- Fundamental
- Price
- BEAM $19.88
- SKE $15.77
- Analyst Decision
- BEAM Strong Buy
- SKE
- Analyst Count
- BEAM 11
- SKE 0
- Target Price
- BEAM $48.90
- SKE N/A
- AVG Volume (30 Days)
- BEAM 2.0M
- SKE 435.1K
- Earning Date
- BEAM 08-05-2025
- SKE 08-07-2025
- Dividend Yield
- BEAM N/A
- SKE N/A
- EPS Growth
- BEAM N/A
- SKE N/A
- EPS
- BEAM N/A
- SKE N/A
- Revenue
- BEAM $63,578,000.00
- SKE N/A
- Revenue This Year
- BEAM N/A
- SKE N/A
- Revenue Next Year
- BEAM $8.82
- SKE N/A
- P/E Ratio
- BEAM N/A
- SKE N/A
- Revenue Growth
- BEAM N/A
- SKE N/A
- 52 Week Low
- BEAM $13.53
- SKE $5.20
- 52 Week High
- BEAM $35.25
- SKE $16.41
- Technical
- Relative Strength Index (RSI)
- BEAM 67.72
- SKE 64.14
- Support Level
- BEAM $16.59
- SKE $14.94
- Resistance Level
- BEAM $17.38
- SKE $16.41
- Average True Range (ATR)
- BEAM 1.09
- SKE 0.57
- MACD
- BEAM 0.24
- SKE -0.00
- Stochastic Oscillator
- BEAM 93.78
- SKE 71.43
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About SKE Skeena Resources Limited
Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.